Market Place
Sourcing Support
AbbVie`s Ubrelvy To Lead $16B+ Migraine Market By 2033 In Major Pharma Nations
11 Sep 2024 //
FIERCE PHARMA
AbbVie`s Ubrelvy Effective Against Early Migraine Signs: Study
30 Aug 2024 //
FIERCE PHARMA
FDA Confirms Paragraph IV Patent Litigation for Ubrogepant Tablets
27 Feb 2024 //
FDA
AbbVie`s Ubrelvy significantly cuts headache pain if taken during prodrome
17 Nov 2023 //
PRESS RELEASE
AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY®
04 Aug 2020 //
PRNEWSWIRE
With DEA scheduling, Lilly`s Reyvow cleared for launch
31 Jan 2020 //
FIERCE PHARMA
Biohaven celebrates PhII/III win for intranasal CGRP migraine drug with Allergan
17 Dec 2019 //
ENDPT NEWS
Allergan`s acute migraine therapy ubrogepant shows strength at Phase 3
20 Nov 2019 //
PHARMAFILE
ICER Releases Draft Evidence Report on Acute Migraine Therapies
08 Nov 2019 //
ICER
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
11 Jul 2019 //
FIERCE PHARMA
Allergan Announces FDA Acceptance of NDA for Ubrogepant
11 Mar 2019 //
PR NEWSWIRE
Eyeing blockbuster migraine market,Allergan unloads +ve PhIII results ubrogepant
28 Apr 2018 //
ENDPTS
Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant
27 Apr 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.